 Antony Waste Handling Cell Ltd Q2 FY2026 consolidated net profit down QoQ to Rs. 13.65 crores
Antony Waste Handling Cell Ltd Q2 FY2026 consolidated net profit down QoQ to Rs. 13.65 crores Eiko Lifesciences Ltd Q2FY26 consolidated PAT increases to Rs. 1.07 crore
Eiko Lifesciences Ltd Q2FY26 consolidated PAT increases to Rs. 1.07 crore LG Balakrishnan and Bros Ltd Q2 FY2026 consolidated net profit soars to Rs. 93.62 crores
LG Balakrishnan and Bros Ltd Q2 FY2026 consolidated net profit soars to Rs. 93.62 crores Mahindra Holidays and Resorts India Ltd posts higher consolidated PAT of Rs. 17.85 crores in Q2FY26
Mahindra Holidays and Resorts India Ltd posts higher consolidated PAT of Rs. 17.85 crores in Q2FY26 Balkrishna Industries Ltd consolidated Q2FY26 PAT falls to Rs. 273.19 crores
Balkrishna Industries Ltd consolidated Q2FY26 PAT falls to Rs. 273.19 crores 
              DEWAN HOUSING: Acquires India's 4th largest housing finance company at 2x trailing book against DHFL at 2.4x; Positive
- Dewan Housing Finance (DHFL) has acquired India's 4th largest standalone housing finance company with a loan book of ~Rs48b as on Sep-10.
- Deutsche Post Bank Home Finance (DPHL) has strong pan-India distribution network with a focus on the metro and non-metro cities.
- DHFL has valued DPHL at 2x trailing book and ~1.6% forward book (FY12). Net worth of DPHL as of 1HFY11 was Rs5.4b and PAT was ~Rs375m.
- DHFL has raised Rs3.5b of subordinated debt and will raise ~Rs4b more to fund acquisition as of now. Cost of debt is ~10.5%.
- Deal will help DHFL to get into upper middle income segment; With the acquisition of DPHL, DHFL will be present across the spectrum.
- The acquisition would boost DHFL's outstanding loans by ~49% (based on FY10 data) and DHFL would be close to achieving balance sheet size of Rs200b by end FY11. This purchase would narrow the gap of DHFL with larger rivals like LIC Housing Finance. Post the acquisition, DHFL would be 40% of LICHF. We will review our numbers post clarity from the management on the accounting treatment. Currently, we maintain our positive view on the stock.